Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095205 · ClinicalTrials.gov registry record · Phase 4
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
A Phase 4 study of Major Depressive Disorder (MDD), sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07095205: Recruiting Phase 4 study of Major Depressive Disorder (MDD), sponsored by Stony Brook University.
NCT07095205 is a Phase 4 study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 14 participants, below the 158-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07095205, a Phase 4 study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.
Primary Outcome
Description: Comparison of Hamilton Depression Rating Scale-17 score at pretreatment and post-treatment. Minimum score 0, maximum possible score 52, with remission defined as \<=7. The higher the score on the scale, the more severe the degree of depression.
Conditions Studied
Interventions
- DRUG Nicotine transdermal patch
- DRUG PET Scan with [18F] VAT
Study Locations (1)
New York
- Stony Brook University: Dept of Psychiatry - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-10-03 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 4 |
What NCT07095205 shows while recruiting
NCT07095205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 158-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Nicotine transdermal patch is the first listed.
NCT07095205 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07095205 about?
NCT07095205 is a clinical study titled "PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.". In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to unde...
What is the current status of trial NCT07095205?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2024-10-03. Estimated completion is 2029-09-30.
What conditions does trial NCT07095205 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT07095205?
The interventions under investigation include: Nicotine transdermal patch (DRUG), PET Scan with [18F] VAT (DRUG).
Who is sponsoring clinical trial NCT07095205?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095205 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07095205's enrollment target sits among peer trials
14 22nd of 22 higher than 1 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Role of mGluR5 in CBT-I
RECRUITING · Phase 4
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
Neurofeedback to Treat Depression - 2
RECRUITING · NA
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy